Author

K. B. Jones

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cell type annotation· 4 Research Focus:differential expression· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:clustering· 2

Frequent Co-Authors

J. Gertz· 2 shared J. M. Vahrenkamp· 2 shared M. L. Nelson· 2 shared A. A. Molinolo· 1 shared A. Al-Ibraheemi· 1 shared A. C. Beck· 1 shared A. C. Hirbe· 1 shared A. Chatzipli· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Gertz

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97

A. Pozner, S. P. Verma, L. Li, S. Wang, J. J. Barrott, M. L. Nelson, J. S. E. Yu, G. L. Negri, S. Colborne, C. S. Hughes, J.-F. Zhu, S. L. Lambert, L. S. Carroll, K. Smith-Fry, M. G. Stewart, , K. B. Jones

This study identifies VCP/p97 as an obligate co-factor of ASPSCR1-TFE3, showing it organizes enhancer loops to drive oncogenic transcription in ASPS and RCC.

bioRxiv · Sep 29, 2023Cancer Biology

YAP-Driven Oral Epithelial Stem Cell Malignant Reprogramming at Single Cell Resolution

F. Faraji, S. I. Ramirez, L. Clubb, K. Sato, V. Burghi, T. S. Hoang, A. Officer, P. Y. Anguiano Quiroz, W. M. Galloway, Z. Mikulski, K. Medetgul-Ernar, P. Marangoni, K. B. Jones, A. A. Molinolo, K. Kim, , J. S. Gutkind

The paper identifies YAP-driven reprogramming of oral epithelial stem cells into tumor-initiating cells using single-cell multiomics, revealing conserved transcriptional programs linked to poor patient survival.

bioRxiv · Jul 24, 2023Cancer Biology

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted by metastasis

M. K. Rahim, T. L. H. Okholm, K. B. Jones, E. E. McCarthy, C. C. Liu, J. L. Yee, S. J. Tamaki, D. M. Marquez, I. Tenvooren, K. Wai, A. Cheung, B. R. Davidson, V. Johri, B. Samad, W. E. O'Gorman, , M. H. Spitzer

The paper examines CD8+ T cell responses in human lymph nodes during cancer immunotherapy and finds that metastasis disrupts these responses.

bioRxiv · Nov 8, 2022 · PreprintImmunology

Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA

I. Cortes-Ciriano, C. D. Steele, K. G. Piculell, A. Al-Ibraheemi, V. Eulo, M. M. Bui, A. Chatzipli, B. C. Dickson, D. C. Borcherding, A. Feber, A. Galor, J. Hart, K. B. Jones, J. T. Jordan, R. H. Kim, , D. T. Miller

This study identifies genomic patterns in MPNST evolution linked to clinical outcomes and shows these patterns are detectable in cell-free DNA.

bioRxiv · May 3, 2022 · PreprintCancer Biology

A system for CBAF reconstitution reveals roles for BAF47 domains and BCL7 in nucleosome ejection

T. S. Mulvihill, M. L. Nelson, N. Verma, K. B. Jones, B. Cairns

The paper develops a system for CBAF reconstitution and creates a nucleosome ejection assay, revealing roles for BAF47 domains and BCL7 in nucleosome ejection.

bioRxiv · Oct 26, 2021 · PreprintBiochemistry

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

bioRxiv · Feb 28, 2021 · PreprintCancer Biology